analysis (Fig. 1B, lower panel, line 3) confirmed that the result obtained in reaction 3 was a false negative.
Isovaleric acidemia (IVA) is an autosomal recessive genetic disorder of the enzyme isovaleryl-CoA dehydrogenase, which is involved in leucine metabolism (1 ) . Clinical symptoms include poor feeding, tachypnea, vomiting (2 ) , listlessness, lethargy, coma (2, 3 ) , and dehydration (4 ) . Individuals homozygous for this defect are characterized primarily by the excretion of isovalerylglycine (2 ) . The metabolic profile may be further complicated by intermediate metabolites such as 3-and 4-hydroxyisovaleric acid (5 ) , methylsuccinic acid (6 ) , methylfumaric acid (7 ), isovalerylglucuronide (8 ) , isovalerylglutamic acid (9 ) , Nisovalerylalanine and N-isovalerylsarcosine (10 ) , isovalerylcarnitine (11 ), 3-hydroxyisoheptanioc acid (12 ) , and alloisoleucine (4 ) . Diagnosis of IVA is based on clinical symptoms and the presence of isovalerylglycine and 3-hydroxyisovaleric acid (13 ) , with some of the above-mentioned metabolites also occurring to a greater or lesser extent (4 ) . Despite the large number of already identified excreted metabolites, their occurrence still does not entirely explain all of the clinical symptoms experienced by these patients. The statement made in 1982 by Duran et al. (14 ) that "[t]he continuing search for 'new' metabolites may eventually lead to a better understanding of the relationship between the clinical conditions and their biochemical abnormalities" is the motivation for our search for previously unidentified metabolites in IVA. In this study, we analyzed the urine of IVA patients for the presence of induced amino acid metabolites not previously identified in IVA.
Most of the amino acid conjugates occurring in the urine of patients with IVA have been detected via gas chromatography-mass spectrometry (GC-MS). Because this technique is not suitable for detection of acetyl and isovaleryl conjugates of tryptophan, lysine, histidine, and asparagine because of their polar characteristics, we identified and quantified these metabolites by electrospray tandem mass spectrometry (ESI-MS-MS). Mass spectra (GC-MS) and daughter-ion profiles (ESI-MS-MS) were obtained by analyses of the chemically synthesized calibrators. These spectra were then used to identify the metabolites in the urine of these patients.
Six IVA patients were investigated for the presence of new urinary metabolites. The concentrations of the diagnostic metabolites found in urine samples from these patients are summarized in Because of the complexity of the profiles and the coelution of organic acids in metabolic disorders, fractionation of the organic acid extract by thin-layer chromatography before GC-MS analysis was necessary. Silica gel 60 F 254 thin-layer chromatography plates (Merck) and a mobile phase consisting of 20 mL of tert-amyl alcohol (Merck Chemicals), 70 mL of chloroform (SARchem), 10 mL of formic acid (Merck), and 5 mL of hexane (BDH) were used for fractionation of the organic acids. A volume of urine equivalent to 26.5 mol of creatinine was extracted by the above-mentioned standard organic acid extraction procedure. After the organic acid solvent was evaporated, the organic acid extract was resuspended in a small volume of methanol for easy application on the thin-layer chromatography plates. The development time of the thin-layer plates was ϳ2 h. The plates were allowed to dry, and the bands were visualized under ultraviolet light and marked with a pencil. The choice of fractions varied depending on the complexity of the visible bands, but the number of bands usually ranged from 6 to 11 per plate. The silica gel containing each band was carefully scraped off the plate; the material was then powdered and placed in a column. The organic acids were eluted from the silica gel with methyl acetate and methanol. The eluate was subsequently dried under nitrogen and derivatized with bis(trimethylsilyl)trifluoroacetamide (Sigma) and trimethylchlorosilane (Sigma). GC-MS analysis was conducted on an Agilent 6890 gas chromatograph equipped with an SE 30 capillary column [25 m ϫ 0.33 mm (i.d)] and ported to an Agilent 5973 mass spectrometer. Extraction and derivatization of urinary isovaleryland acetyl-amino acid conjugates were performed by the standard organic acid solvent extraction method as described previously (17 ) .
ESI-MS-MS identification of the amino acid conjugates was done by use of a characteristic fragment in the daughter-ion profile and identification of the mother ion of mass characteristic of the pseudomolecular ion (M ϩ ) of the conjugate of interest, with the characteristic daughter-ion and pseudomolecular ion masses for each compound shown in L of urine or synthesized sample. These were then dried at 70°C under reduced pressure. Butanolic HCl (3 mol/L) was then added, and the mixture was butylated for 10 min at 70°C and dried at 70°C under reduced pressure. After the dried samples were resuspended in 100 L of 50:50 acetonitrile-water containing 10 mL/L formic acid, they were centrifuged at 16 000g for 10 min to remove any materials blocking the capillary tube. The samples were introduced into the electrospray source at a rate of 10 L/min. ESI-MS-MS analyses and conditions were carried out as described previously (18 ) . Formerly unidentified isovaleryl conjugates of the following amino acids were detected and identified in the urine of IVA patients: ␣-aminobutyric acid, aspartic acid, serine, phenylalanine, threonine, valine, leucine, and tyrosine by GC-MS; and N-isovalerylasparagine, -histidine, -lysine, and -tryptophan by ESI-MS-MS. Acetylated conjugates of the following amino acids were also detected: threonine, valine, glycine, ␤-alanine, ␣-alanine, and tyrosine by GC-MS and tryptophan by ESI-MS-MS. Both the concentrations and the characteristic mass spectra of all of the above-mentioned conjugates are given in the online Data Supplement (Supplemental Data Table 2 and Supplemental Data Figs. 1-19, respectively) . As expected, the concentrations of the acetylated conjugates were higher in the 2 patients with ketosis at the time of urine collection because of the increased acetyl-CoA production that occurs during ketotic episodes.
These results indicate that as a detoxification mechanism the body uses a variety of amino acids to conjugate accumulating isovaleric and acetic acid. The 19 isovaleryland acetyl-amino acid conjugate metabolites identified in this study give a more complete biochemical profile of IVA patients, which may lead to better understanding and treatment of this disease. The new mass spectra and the methods used to obtain them also may serve as a useful resource for investigation of other inherited metabolic disorders. Chronic heart failure (CHF) is a major public health problem causing considerable morbidity and mortality (1-3 ) . Prevention of CHF by identifying risk factors is therefore a major issue. Previous studies found that hypertension, smoking, diabetes mellitus, obesity, and advancing age are the most important risk factors for CHF (4 ) . Recently, plasma homocysteine (Hcy) has been suggested as a newly recognized risk factor (5, 6 ) . However, there are no data regarding the association between Hcy and various objective as well as subjective measures of CHF. The demonstration of such relationships would help to clarify the role of hyperhomocysteinemia in CHF. We hypothesized that plasma Hcy is associated with clinical and echocardiographic signs of CHF as well as with N-terminal pro-brain natriuretic peptide (NT-proBNP), suggesting a relationship between Hcy and the severity of CHF. Accordingly, we investigated the relationships of plasma Hcy with serum NT-proBNP and clinical and echocardiographic indices of CHF in patients and in controls.
For this study, 95 patients with systolic CHF and 12 healthy persons without cardiac diseases were interviewed and examined by the same 2 experienced cardiologists, who were blinded to the study. All participants had a medical history, physical examination, venous blood sampling, 6-min walking test (6-MWT), electrocardiography, and echocardiography. Eighty-two patients underwent a cardiac catheterization according to the American Heart Association guidelines (7 ) . Additionally, 37 patients performed a symptom-limited bicycle exercise test (Ergoline cardio-systems) with gas-exchange analysis (MedGraphics CPX/D spiroergometry system; Medical Graphics Corporation) to determine maximum oxygen uptake (Vo 2max ). Informed consent was obtained from all participants, and the study protocol was approved by the Institutional Review Board.
Nonfasting venous blood samples (plasma and serum) were drawn during the office visits and centrifuged within 45 min. Total Hcy was measured in EDTA-plasma by an HPLC application (Immundiagnostik) according to the method of Araki and Sato (8 ) . Inter-and intraassay CVs were Ͻ5.1%. Serum NT-proBNP and cardiac troponin T were measured with commercial chemiluminescence assays on an Elecsys 2010 analyzer (Roche Diagnostics). Intra-and interassay CVs were Ͻ2.7% and Ͻ3.2%, respectively, at concentrations Ն175 ng/L.
Anthropometric data are provided as the mean (SD) and were compared by a Student t-test. Because Hcy and NT-proBNP were not normally distributed, we performed a logarithmic transformation before further data exploration. We then performed a Pearson correlation analysis. Hcy and NT-proBNP are influenced by renal function and age; we therefore also calculated a partial correlation controlling for age and creatinine. Calculations were done with the software package SPSS 11.0 (SPSS Inc.).
Most of the patients investigated were classified as New York Heart Association (NYHA) classes II (n ϭ 27) and III (n ϭ 39; Table 1 ). The mean age increased (P ϭ 0.03) with increasing NYHA class [controls, 44 (10) years; NYHA class I, 51 (16) years; NYHA class II, 53 (11) years; NYHA class III, 55 (12) years; NYHA class IV, 61 (15) years]. Weight and height did not differ among the NYHA classes. As expected, physical performance decreased with increasing NYHA classes. The 6-MWT decreased from 530 (70) m in controls to 26 (82) m in NYHA class IV patients (P Ͻ0.001). Additionally, Vo 2max decreased from 25 (13) mL ⅐ min Ϫ1 ⅐ (kg body weight) Ϫ1 in NYHA class I patients to 16 (4) mL ⅐ min Ϫ1 ⅐ (kg body weight) Ϫ1 in
